Cite
HARVARD Citation
Shi, Y. et al. (2019). CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial. Cancer communications. 39 (1), pp. 1-13. [Online].